Pathstone Holdings
GILD icon

Pathstone Holdings’s Gilead Sciences GILD Stock Holding History

Pathstone Holdings’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17M Buy
134,083
+16,110
+14% +$2.12M 0.05% 236
2026
Q1 		$16.4M Buy
117,973
+3,663
+3% +$513K 0.07% 210
2025
Q4 		$14M Buy
114,310
+3,009
+3% +$366K 0.05% 239
2025
Q3 		$12.4M Buy
111,301
+1,035
+0.9% +$118K 0.05% 281
2025
Q2 		$12.2M Buy
110,266
+3,930
+4% +$418K 0.05% 268
2025
Q1 		$11.9M Buy
106,336
+1,611
+2% +$166K 0.05% 281
2024
Q4 		$9.67M Buy
104,725
+3,677
+4% +$331K 0.04% 326
2024
Q3 		$8.47M Buy
101,048
+891
+0.9% +$68K 0.04% 385
2024
Q2 		$6.87M Sell
100,157
-13,724
-12% -$916K 0.03% 425
2024
Q1 		$8.34M Sell
113,881
-1,709
-1% -$131K 0.04% 356
2023
Q4 		$9.4M Buy
+115,590
New +$8.99M 0.05% 268

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pathstone Holdings's GILD Position: Q2 2026 in Review

Pathstone Holdings increased its Gilead Sciences (GILD) stake by 14% in Q2 2026, buying an estimated $2.12M and bringing the position to 134,083 shares worth $17M. The position accounts for 0.05% of the portfolio, ranked #236.

Pathstone Holdings first reported a position in GILD in Q4 2023 and has held it in 11 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Pathstone Holdings held 134,083 shares of Gilead Sciences worth $17M as of Q2 2026.
  • Pathstone Holdings bought 16,110 Gilead Sciences shares in Q2 2026, an estimated $2.12M.
  • Gilead Sciences made up 0.05% of Pathstone Holdings's portfolio in Q2 2026, its #236 holding.
  • Pathstone Holdings first reported a position in Gilead Sciences in Q4 2023 and has held it in 11 quarters since.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.